Bristol-Myers Squibb Company (NYSE:BMY) EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Bristol-Myers Squibb Company (BMY) traded down $0.45 during trading on Wednesday, hitting $62.02. 4,828,800 shares of the stock traded hands, compared to its average volume of 8,452,800. The company has a market capitalization of $102,244.66, a PE ratio of 21.10, a P/E/G ratio of 2.37 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.77 EPS. sell-side analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. Massey Quick Simon & CO. LLC increased its position in Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares during the last quarter. Horan Capital Advisors LLC. bought a new position in Bristol-Myers Squibb during the third quarter valued at $122,000. Tradewinds Capital Management LLC increased its position in Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 500 shares during the last quarter. Atlantic Trust LLC bought a new position in Bristol-Myers Squibb during the second quarter valued at $111,000. Finally, AllSquare Wealth Management LLC bought a new position in Bristol-Myers Squibb during the third quarter valued at $134,000. Hedge funds and other institutional investors own 69.82% of the company’s stock.
A number of analysts have recently issued reports on the stock. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price target on the stock. in a report on Tuesday, August 22nd. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Wednesday, October 25th. BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. Credit Suisse Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Wednesday, August 16th. Finally, Cowen set a $65.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, August 14th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $64.93.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/06/bristol-myers-squibb-company-bmy-evp-sandra-leung-sells-156582-shares.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.